Davenport & Co LLC Reduces Enovis Corp Holdings Amid Mixed Performance Indicators
ByAinvest
Sunday, Aug 17, 2025 6:07 am ET1min read
ENOV--
Enovis Corp, a medical technology company, operates through the Prevention & Recovery and Reconstructive segments. The Prevention & Recovery segment focuses on orthopedic solutions and recovery sciences, while the Reconstructive segment handles surgical implants and productivity tools [2].
The company reported strong earnings for the second quarter of 2025. Revenue reached $564.5 million, exceeding analyst estimates by 7.5% year-on-year growth and a 2% beat. Adjusted EPS was $0.79, surpassing estimates by 9.9% and a 2.9% beat. Adjusted EBITDA was $97.2 million, up 17.2% margin and a 2.9% beat. The company lifted its full-year revenue and Adjusted EPS guidance, with revenue expected to reach $2.26 billion and Adjusted EPS to $3.13 [1].
The stock has experienced a 10.26% gain since the transaction but a -33.3% year-to-date price change. Enovis Corp currently trades at $29.59, up from $25.75 just before the earnings announcement [1].
Analysts have highlighted several key topics during Enovis's Q2 earnings call, including the impact of new product launches, the transparency of adjusted EBITDA metrics, and the company's strategy to maintain leadership in the competitive shoulder market [1].
References:
[1] https://finance.yahoo.com/news/top-5-analyst-questions-enovis-053451864.html
[2] https://www.marketbeat.com/stocks/NYSE/ENOV/
Davenport & Co LLC reduced its Enovis Corp holdings by 86,865 shares, impacting its portfolio by -0.01%. The firm now holds 2,756,270 shares of Enovis Corp, with a 4.83% ratio of the firm's holdings in the stock. The transaction was executed at $26.8 per share. Enovis Corp has a market capitalization of $1.69 billion and generates most revenue from the Prevention & Recovery segment. The company has experienced a 10.26% gain since the transaction but a -33.3% year-to-date price change.
Davenport & Co LLC recently reduced its holdings in Enovis Corp by 86,865 shares, impacting its portfolio by -0.01%. The firm now holds 2,756,270 shares of Enovis Corp, representing a 4.83% ratio of its total holdings in the stock. The transaction was executed at $26.8 per share [1].Enovis Corp, a medical technology company, operates through the Prevention & Recovery and Reconstructive segments. The Prevention & Recovery segment focuses on orthopedic solutions and recovery sciences, while the Reconstructive segment handles surgical implants and productivity tools [2].
The company reported strong earnings for the second quarter of 2025. Revenue reached $564.5 million, exceeding analyst estimates by 7.5% year-on-year growth and a 2% beat. Adjusted EPS was $0.79, surpassing estimates by 9.9% and a 2.9% beat. Adjusted EBITDA was $97.2 million, up 17.2% margin and a 2.9% beat. The company lifted its full-year revenue and Adjusted EPS guidance, with revenue expected to reach $2.26 billion and Adjusted EPS to $3.13 [1].
The stock has experienced a 10.26% gain since the transaction but a -33.3% year-to-date price change. Enovis Corp currently trades at $29.59, up from $25.75 just before the earnings announcement [1].
Analysts have highlighted several key topics during Enovis's Q2 earnings call, including the impact of new product launches, the transparency of adjusted EBITDA metrics, and the company's strategy to maintain leadership in the competitive shoulder market [1].
References:
[1] https://finance.yahoo.com/news/top-5-analyst-questions-enovis-053451864.html
[2] https://www.marketbeat.com/stocks/NYSE/ENOV/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet